Treatment for Facial Psoriasis
For psoriasis on the face, use calcipotriene combined with hydrocortisone for 8 weeks as first-line therapy, or alternatively, tacrolimus 0.1% ointment for up to 8 weeks. 1
Primary Treatment Options
Calcipotriene Plus Low-Potency Corticosteroid (Preferred)
- Calcipotriene combined with hydrocortisone 10 mg/g applied once daily for 8 weeks is specifically recommended for facial psoriasis (Strength of Recommendation: B). 1
- In a randomized trial of 409 patients, treatments containing hydrocortisone were significantly more effective on the face than calcipotriene alone (odds ratio 2.01, P = 0.001). 1
- The combination also demonstrated superior tolerability compared to calcipotriene monotherapy, with significantly fewer adverse drug reactions on facial skin (P < 0.001). 2
Tacrolimus 0.1% Ointment (Alternative First-Line)
- Off-label use of tacrolimus 0.1% ointment twice daily for up to 8 weeks is recommended for facial psoriasis (Strength of Recommendation: B). 1
- In a double-blind RCT of 167 patients with facial psoriasis, 65% achieved clear or almost clear status with tacrolimus 0.1% versus 31% with placebo after 8 weeks (P < 0.001). 1
- An open-label trial showed 81% of patients achieved complete clearance by day 57, with no development of atrophy, telangiectasia, or striae. 3
- Tacrolimus is particularly valuable as a steroid-sparing agent for prolonged use (≥4 weeks) on thin facial skin. 1
Why These Agents for Facial Psoriasis
Avoid High-Potency Corticosteroids
- The face is at greatest risk for corticosteroid-induced adverse effects including skin atrophy, striae, telangiectasia, and perioral dermatitis. 1
- High-potency corticosteroids may exacerbate acne and rosacea on facial skin. 1
Mechanism Considerations
- Calcipotriene (vitamin D analogue) inhibits keratinocyte proliferation and enhances differentiation without causing skin atrophy. 1
- Tacrolimus blocks T-cell activation and proinflammatory cytokine synthesis without the atrophogenic effects of corticosteroids. 1
Treatment Algorithm
Step 1: Initial Therapy (First 8 Weeks)
- Start with calcipotriene/hydrocortisone combination once daily, OR
- Use tacrolimus 0.1% ointment twice daily if patient has history of corticosteroid side effects or prefers steroid-free option. 1
Step 2: If Inadequate Response
- Consider pimecrolimus 0.1% cream twice daily for 8 weeks (off-label, Strength of Recommendation: B). 1
- Evaluate for need to escalate to phototherapy or systemic therapy if topical treatments fail. 4
Step 3: Maintenance (After Clearance)
- Continue with the effective agent at reduced frequency to prevent relapse. 1
- Avoid abrupt discontinuation of corticosteroids to prevent rebound. 1
Important Caveats
Calcipotriene-Specific Warnings
- Do not combine calcipotriene with salicylic acid—the acidic pH inactivates calcipotriene and reduces effectiveness. 1
- Apply after phototherapy if using both modalities, as UVA radiation decreases calcipotriene concentration. 1
- Efficacy may not be evident until 8 weeks of treatment. 1
Tacrolimus-Specific Warnings
- Patients may experience burning and pruritus initially, which typically improves with continued use. 1
- Avoid application to moist skin to minimize burning sensation. 1
- FDA boxed warning exists regarding theoretical lymphoma risk, though no evidence supports increased malignancy risk with topical use. 1
Formulation Selection
- Choose ointment formulations for dry, scaly facial lesions; cream formulations for less hyperkeratotic presentations. 4
- Patient preference regarding vehicle is critical for adherence. 4